Takeda Pharmaceutical (NYSE:TAK) General Counsel Sells 30,868 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) General Counsel Natalie Anne Marie Furney sold 30,868 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $527,842.80. Following the completion of the transaction, the general counsel directly owned 204,298 shares in the company, valued at $3,493,495.80. The trade was a 13.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock traded down $0.06 during trading hours on Wednesday, reaching $17.42. 2,004,364 shares of the stock traded hands, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The firm has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The company has a 50 day moving average price of $16.49 and a 200 day moving average price of $17.13.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Valeo Financial Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 6.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after buying an additional 632 shares during the period. Franklin Resources Inc. lifted its stake in Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares during the period. Abel Hall LLC grew its holdings in Takeda Pharmaceutical by 2.3% during the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after acquiring an additional 781 shares in the last quarter. Private Trust Co. NA grew its holdings in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its position in Takeda Pharmaceutical by 5.7% during the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after purchasing an additional 786 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TAK shares. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.